The US Food and Drug Administration (FDA) has accepted for review Viatris and Mapi Pharma’s new drug application (NDA) which has been filed for GA Depot.
A Prescription Drug User Fee Act target action date of 8 March 2024 was assigned by the FDA.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The 40mg product is a long-acting glatiramer acetate (GA) to treat relapsing forms of multiple sclerosis (RMS/MS). It is administered as a monthly injection.
The filing is supported by data from a Phase III study that compared the safety, tolerability and efficacy of GA Depot with placebo.
This multinational, double-blind, placebo-controlled study enrolled 1,016 subjects who received either 40mg of GA Depot or a placebo.
Both groups received the treatment once every four weeks for a total of 13 doses via intramuscular injection.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe product offered a preferable schedule and anticipated fewer injection site reactions than other GA candidates.
A statistically significantly reduced annualised relapse rate of 30.1% against placebo (p=0.0066) was observed, a primary endpoint of the study.
Mapi Pharma CEO and chairman Ehud Marom stated: “We are confident that GA Depot, when approved, will represent an important advancement in MS care by offering a convenient once-monthly option for patients which may potentially improve compliance and adherence, and the medicine is well positioned to deliver on this important unmet need.
“I commend the teams at Mapi and Viatris for the strong collaboration which has leveraged our collective expertise in complex products to deliver this novel medicine.”
Commercially available as Copaxon, GA Depot is a long-acting injection version of the approved GA.
It is also currently being studied in a Phase II trial in patients with primary progressive multiple sclerosis.
